Trillium Asset Management LLC Sells 1,855 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Trillium Asset Management LLC lowered its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 64,265 shares of the medical research company’s stock after selling 1,855 shares during the period. Trillium Asset Management LLC’s holdings in IQVIA were worth $12,629,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Avior Wealth Management LLC grew its holdings in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the last quarter. Synergy Asset Management LLC bought a new stake in IQVIA in the 4th quarter worth $33,000. Assetmark Inc. grew its holdings in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares during the last quarter. Meeder Asset Management Inc. grew its holdings in IQVIA by 353.7% in the 3rd quarter. Meeder Asset Management Inc. now owns 245 shares of the medical research company’s stock worth $58,000 after acquiring an additional 191 shares during the last quarter. Finally, Versant Capital Management Inc grew its holdings in IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after acquiring an additional 93 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on IQV shares. Citigroup cut their price target on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Robert W. Baird cut their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Barclays cut their price target on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. William Blair reissued an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Finally, Leerink Partners reaffirmed an “outperform” rating and issued a $248.00 target price (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Stock Up 1.9 %

NYSE:IQV opened at $188.45 on Wednesday. The firm has a market cap of $33.23 billion, a P/E ratio of 25.13, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $256.34. The firm has a 50-day simple moving average of $196.06 and a two-hundred day simple moving average of $209.52.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.